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Summary dently and have a relatively mild phenotype, with onset
at ú18 mo of age.
The survival motor neuron (SMN) transcript is encoded
All three forms of SMA have been mapped, by linkageby two genes, SMNT and SMNC. The autosomal reces-
analysis, to 5q11.2-q13.3 (Brzustowicz et al. 1990;sive proximal spinal muscular atrophy that maps to
Melki et al. 1990; Simard et al. 1992; Brahe et al. 1994;5q12 is caused by mutations in the SMNT gene. The
Burghes et al. 1994a; Wirth et al. 1994; Wirth et al.SMNT gene can be distinguished from the SMNC gene
1995a), to a region that contains multiple copies ofby base-pair changes in exons 7 and 8. SMNT exon 7
genes and markers (Francis et al. 1993; Kleyn et al.is not detected in Ç95% of SMA cases due to either
1993; Carpten et al. 1994; Melki et al. 1994; Lefebvredeletion or sequence-conversion events. Small mutations
et al. 1995; Roy et al. 1995; Thompson et al. 1995).in SMNT now have been identiﬁed in some of the re-
Analysis of these multicopy markers showed speciﬁc al-maining nondeletion patients. However, there is no reli-
leles associated with SMA, loss of a copy of the markerable quantitative assay for SMNT, to distinguish SMA
inÇ50% of severe SMA cases, and deletion of all copiescompound heterozygotes from non-5q SMA-like cases
of the marker on some SMA chromosomes (Burghes et(phenocopies) and to accurately determine carrier status.
al. 1994b; DiDonato et al. 1994; Melki et al. 1994;We have developed a quantitative PCR assay for the
Lefebvre et al. 1995; Wirth et al. 1995b).determination of SMNT and SMNC gene-copy number.
Three cDNAs have been reported that detect deletionsThis report demonstrates how risk estimates for the di-
in SMA patients (Lefebvre et al. 1995; Roy et al. 1995.;agnosis and detection of SMA carriers can be modiﬁed
Thompson et al. 1995). Neuronal apoptosis inhibitoryby the accurate determination of SMNT copy number.
protein (NAIP) and XS2G3 are deleted in 50% of type
I SMA patients (Roy et al. 1995; Thompson et al. 1995),
which most likely represents the extent of the deletion on
Introduction severe SMA chromosomes (Wirth et al. 1995b; Simard et
al., in press). The third cDNA, the survival motor neu-Proximal spinal muscular atrophy (SMA) is an autoso-
ron, is encoded by SMNT and SMNC, two nearly identi-mal recessive disorder resulting in the loss of a motor
cal genes that can be distinguished by base changes inneurons in the spinal cord. SMA has an estimated inci-
exons 7 and 8 (Lefebvre et al. 1995; van der Steege etdence of 1/10,000, with a carrier frequency of 1/40–
al. 1995). The SMNT gene is not detectable in Ç95%1/60 (Pearn 1980; Melki et al. 1994). The recessive
of SMA patients, either because of conversion of se-proximal childhood SMAs can be classiﬁed clinically
quences in the SMNT gene to those in the SMNC geneinto three groups. Type I (Werdnig-Hoffmann) is the
or as a result of SMNT gene deletions (Hahnen et al.most severe form, with onset at õ6 mo of age and with
1995, 1996; Lefebvre et al. 1995; Rodrigues et al. 1995;death typically at õ2 years of age. Type II SMA patients
van der Steege et al. 1996; Velasco et al. 1996; DiDonatodisplay an intermediate severity, with onset at õ18 mo
et al. 1997b ). Several small mutations in the SMNT geneof age and with an inability to walk. Type III (Kugel-
have been reported in patients without a deleted or se-burg-Welander) individuals are able to walk indepen-
quence-converted SMNT allele. These mutations include
disrupted splicing of exon 7 (Lefebvre et al. 1995), dele-
tion of 4 bp (Bussaglia et al. 1995) or 5 bp (Brahe et al.Received January 28, 1997; accepted for publication March 21,
1996) in exon 3, an 11-bp duplication in exon 6 (Par-1997.
Address for correspondence and reprints: Dr. Thomas W. Prior, sons et al. 1996), and a clustering of missense mutations
Department of Pathology, Ohio State University, 121 Hamilton Hall, in exon 6 (Lefebvre et al. 1995; Hahnen et al. 1997;
1645 Neil Avenue, Columbus, OH 43210. Talbot et al. 1997). These mutations provide strong evi- 1997 by The American Society of Human Genetics. All rights reserved.
0002-9297/97/6006-0019$02.00 dence that SMNT is the primary SMA-determining gene.
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The absence of detectable SMNT exons 7 and 8 in tients did not necessarily conform to all criteria deﬁned
by the SMA consortium, since most were referred forSMA patients is being utilized as a powerful diagnostic
test for SMA (van der Steege et al. 1995). Although the diagnostic purposes. A small number of the samples
were collected for prior genetic studies, which did con-test has a sensitivity of Ç95%, the assay is not quantita-
tive, and it cannot detect individuals with heterozygous form to the diagnostic criteria outlined by the interna-
tional SMA consortium. We also performed the SMNTdeletions of SMNT. Thus, it is not possible to identify
SMA carriers and to distinguish between a non-5q SMA- and SMNC copy-number assay on 54 normal, unselected
individuals and on 79 SMA carriers previously charac-like patient (in whom both chromosomes contain
SMNT) and a compound heterozygote 5q SMA patient terized by Ag1-CA segregation analysis (DiDonato et al.
1994). Patient 4659 is a 24-year-old male diagnosed(in whom SMNT is absent on one chromosome and an
unknown alteration in the SMNT gene is present on with SMA type III, by muscle biopsy, at age 14 years.
the other chromosome). Since SMNT is homozygously
Synthesis of Internal Standardsdeleted in 95% of 5q SMA cases, then, according to
Hardy-Weinburg equilibrium, virtually all the remaining Two internal standards were constructed for the
SMNT and SMNC copy-number assay. These standards5q SMA individuals should have a heterozygous dele-
tion. The marker Ag1-CA (C272) lies at the 5 end of have internal deletions of 20–50 bp, so that they are
ampliﬁed with the same primer pairs as their genomicthe SMN genes (Burglen et al. 1996) and has been shown
to vary, from zero to three copies, on a chromosome counterparts but can be distinguished by size (Celi et al.
1993). Incorporation of equimolar amounts of internal(DiDonato et al. 1994; Wirth et al. 1995b). This indi-
cates that the copy number of SMN genes also varies standards in the competitive PCR reaction was used to
standardize the amount of input genomic DNA and toon chromosomes. Previous attempts to determine the
copy number of the SMNT gene have measured the ratio monitor the efﬁciency of the reaction. Genomic DNA
was used as a template to generate the in vitro–synthe-of SMNT to SMNC; however, this has serious draw-
backs. sized CFTR internal standard. The 50-ml PCR reaction
contained 200 ng genomic DNA, 3 mM MgCl2, 11 TaqIn this paper, we describe a competitive PCR strategy
to determine the SMNT and SMNC gene-copy number. DNA polymerase buffer (USB), 200 mM each dNTP,
30 ng each of CF621F(5-AGTCACCAAAGCAGTAC-The assay uses an exon from the cystic ﬁbrosis trans-
membrane regulator (CFTR) as a standard to determine AGC-3; Zielenski et al. 1991) and CFTR-IS (5-GGG-
CCTGTGCAAGGAAGTGTTAAGCTATTCTCATCT-the relative dosage of SMNT and SMNC and thus avoids
bias due to ﬂuctuations in the copy number of SMNC. GCATTCCA-3) primers, and 0.5 U Taq DNA
polymerase (USB). Diluted plasmid DNA containing aWe demonstrate that this assay is capable of accurately
distinguishing compound heterozygotes from non-5q portion of the SMNT gene was used as a template to
generate the in vitro–synthesized SMN internal stan-SMA-like cases. In a type III patient who lacked one
copy of SMNT, we found a novel missense mutation in dard. The 50-ml reaction contained components similar
to those in the CFTR internal standard reaction, exceptexon 6. Analysis of normal and carrier individuals by
this assay clearly indicates that the copy number of that primers R111 (5-AGACTATCAACTTAATTT-
CTGATCA-3; Lefebvre et al. 1995) and SMN-IS (5-SMNT and SMNC varies from zero to at least two per
chromosome and that the majority of SMA carriers have CCTTCCTTCTTTTTGATTTTGTTTATAGCTATA-
TAGACATAGATAGCTA-3) were used. The reactionsa single copy of the SMNT gene on their normal chromo-
some. This report demonstrates that it now is possible were denatured at 95C for 5 min, then run for 35 cycles
at 95C 1 min, 55C 2 min, and 72C 3 min (Ericompto directly identify SMA carriers and affected compound
heterozygotes by the accurate determination of SMNT Thermocycler). The products were subcloned into pCR
2.1 (Invitrogen), and plasmid DNA was puriﬁed. Wecopy number.
found the use of cloned plasmid DNA more reliable than
diluted PCR products. The inserts were excised withMaterial and Methods
EcoRI and were stored at 070C.
Patient Samples and DNA Isolation
SMNT and SMNC Copy-Number AssayDNA was isolated from peripheral venous blood or
lymphoblast cell lines by the salting-out procedure Two competitive PCR ampliﬁcations were performed.
In the ﬁrst reaction, the DNA concentration of each(Miller et al. 1988) or by organic extraction (Sambrook
et al. 1989). A total of 76 patients (64 from Ohio State sample was determined by estimation of the number of
genome equivalents, according to the method of SestiniUniversity [OSU], 8 from Hoˆpital Sainte-Justine, Mon-
treal [HSJ], and 4 from the Hospital for Sick Children, et al. (1995). Approximately 200 ng genomic DNA
(Ç60,000 genome equivalents), determined on the basisToronto [HSC]) with a potential diagnosis of SMA were
analyzed to identify compound heterozygotes. These pa- of spectrophotometric quantitation, was ampliﬁed in the
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presence of 60,000 CFTR-IS competitor molecules with ageQuantTM software. Thus, the SMNT and SMNC
copy-number assay was performed independently byCF621F and CF621R (5-GGGCCTGTGCAAGGA-
AGTGTTA-3 [Zielenski et al. 1991]) primers. The 25- two groups and was quantitated by two different meth-
ods. Similar ratios were obtained, which demonstratesml PCR reaction contained 3 mM MgCl2, 1 1 Taq DNA
polymerase buffer (USB), 200 mM each dNTP, 15 ng the versatility of this method.
each CF621 primer, 0.5 U Taq DNA polymerase (USB), The quantitative PCR assay to measure SMNT and
and 1 ml (60,000 copies) CFTR internal standard. The SMNC gene copy number provides clear advantages over
reaction conditions consisted of an initial denaturation existing methods; however, a few technical points
at 95C for 5 min, followed by 30 cycles of 95C 1 should be addressed, since the assay is subject to the
min, 55C 2 min, and 72C 3 min. The products were potential problems of quantitative PCR. It is important
electrophoresed on an 8% polyacrylamide gel and were to control for the amount of input genomic DNA, to
stained with ethidium bromide. The band intensities avoid inaccuracies in the quantitation of copy number
were evaluated, and the target genomic DNA for the (Celi et al. 1994). We observed a small degree of vari-
SMN-dosage assay was adjusted accordingly. ability in the ampliﬁcation efﬁciency of SMN-IS, espe-
In the second competitive PCR reaction, R111 and cially when comparing DNA samples extracted by dif-
CF621F primers (15 ng each) were end-labeled with 0.1 ferent methods. Therefore, we recommend the use of
ml [g32P]ATP (10 mCi/ml; Amersham) and T4 DNA ki- normal, carrier, and affected controls prepared by the
nase (Gibco BRL) at 37C for 20 min. The 25-ml PCR same extraction method as is used for the samples being
reaction contained 200 ng genomic DNA, 3 mM MgCl2, tested. Both autoradiography and phosphoimaging were
1 1 Taq DNA polymerase buffer (USB), 200 mM each effective and accurate methods to quantitate copy num-
dNTP, end-labeled forward primers, 15 ng each of ber, but standard precautions, such as preﬂashing the
CF621R and X-7 Dra (5-CCTTCCTTCTTTTTGATT- ﬁlm and monitoring exposure times, must be taken, to
TTGTTT-3; van der Steege et al. 1995) primers, 0.5 U ensure the linearity of ﬁlm response for autoradiogra-
Taq DNA polymerase (USB), and 1 ml (60,000 copies) phy.
each of CFTR and SMN internal standards. The reaction
conditions consisted of an initial denaturation at 95C PCR Ampliﬁcation of SMN for Mutation Detection
for 5 min, followed by 16 cycles of 95C 1 min, 55C PCR primers used for ampliﬁcation of SMN exons
2 min, and 72C 3 min. The PCR product (8 ml) was were selected on the basis of published intron/exon
digested with 20 U DraI (New England Biolabs) over- boundary sequences (Burglen et al. 1996) and primer
night at 37C. An SMA-patient sample with a homozy- sequences kindly provided by Dr. Judith Melki (Hoˆpital
gous deletion of SMNT always was run as a control, to des Enfants Malades, Paris). For samples with one copy
check for complete digestion with DraI. The digested of SMNT, each SMN exon was ampliﬁed from genomic
samples were run on a 6% denaturing polyacrylamide DNA and was subjected to SSCP analysis as described
gel and were quantitated by autoradiography. Hyper- elsewhere (Parsons et al. 1996). SMN exon 6 was PCR
ﬁlm-MP (Amersham) was preﬂashed with a unit (Amer- ampliﬁed by use of 30 ng each of primers 541C618 (5-
sham) to ensure linearity of ﬁlm response (Laskey and CTCCCATATGTCCAGATTCTCTTG-3) and EX63
Mills 1975). The gel was exposed for 16–24 and 48– (5-AAGAGTAATTTAAGCCTCAGACAG-3) in a 50-
72 h at 070C. Densitometry of the bands was per-
ml reaction mixture containing 1 U Taq polymerase (Per-
formed on a Shimadzu CS-9000. The genomic SMNT/ kin Elmer), 0.5 mM each dNTP, 3 mM MgCl2, and 1 1genomic CFTR and genomic SMNC/genomic CFTR ra-
PCR buffer (670 mM Tris, 100 mM b-mercaptoethanol,
tios were determined for all samples. Since there are two
166 mM ammonium sulfate, 67 mM EDTA, and 0.5
copies of CFTR per genome, the SMN/CFTR ratio was
mg BSA/ml). The PCR reaction consisted of an initial
used to determine the relative dosage or copy number
denaturation step at 95C for 5 min, followed by 35of SMNT and SMNC genes.
cycles of 95C for 1 min, 55C for 2 min, and 72C forThe assay was performed at HSJ, with the following
3 min, with a ﬁnal extension for 8 min at 72C.modiﬁcations. The CF621F and R111 primers were end-
labeled with [g33P]ATP from ICN. The PCR conditions
Heteroduplex Analysisincluded a hot start with the addition of 1 U Taq DNA
To allow heteroduplex formation, PCR products werepolymerase (Gibco BRL), followed by 20 cycles of 94C
heated to 95C for 5 min and then incubated at 37C1 min, 55C 1 min, and 72C 1 min (MJ Research ther-
for 30 min. Fifteen microliters of the PCR product wasmocycler). The PCR products were digested with DraI
mixed with 2.5 ml of 6 1 MDETM gel loading buffer and(Gibco BRL). The dried gels were exposed in a phosphor
was electrophoresed on a 50-cm vertical, 0.8-mm-thickscreen for 72 h and were scanned by use of a Phos-
MDETM gel (FMC) for 15 h at 1,000 V. The gel wasphorImager SITM (Molecular Dynamics). Products of
each PCR reaction were quantitated by use of the Im- stained in a solution of 0.6 1 Tris-borate EDTA con-
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taining 1 mg ethidium bromide/ml and was photo- ized an SMA carrier with one copy of SMNC, not all
carriers have one copy of SMNC.) There was no overlapgraphed under UV light.
in the SMNT/CFTR or SMNC/CFTR ratios, within 2 SD
Reverse-Transcriptase–PCR (RT-PCR) of the mean, between the normal and carrier individuals.
The described quantitative PCR assay demonstrates highTotal RNA was isolated from peripheral blood lym-
precision between different gel runs and therefore canphocytes by use of TRIzolTM Reagent (Gibco BRL).
distinguish reliably between individuals with one andFirst-strand cDNA synthesis was performed with 2 mg
two copies of SMNT and SMNC.total RNA, oligo(dT), and Superscript II RNase H0 Re-
We then studied a population of patients referred forverse Transcriptase (200 U/ml; Gibco BRL), according
SMA diagnostic testing who were not homozygouslyto the manufacturer’s instructions. The single-stranded
deleted for SMNT exons 7 and 8 by either SSCP analysiscDNAs were PCR ampliﬁed by use of 30 ng each of
or the restriction-enzyme assay. Seventy-six nondeletionthe exon 6 forward primer 541C618 and the exon 8
samples were analyzed by use of the quantitative PCRreverse primer 541C1120 (5-CTACAACACCCTTCT-
assay, and the results for those individuals with a singleCACAG-3), with reaction mixture components and
copy of SMNT are shown in table 2. A heterozygousPCR conditions identical to those used for PCR ampliﬁ-
deletion of SMNT was detected in 6/76 (Ç8%) individu-cation of SMN exon 6.
als. Heteroduplex or SSCP analysis of the single SMNT
Subcloning and Sequencing copy present in these patients revealed abnormal bands
in 3/6 patients. Mutations have been detected in 2/6PCR and RT-PCR ampliﬁcation products were sub-
individuals (1 type I SMA [Parsons et al. 1996] and 1cloned into a TA cloning vector (Invitrogen), according
type III patient described below), and the other individ-to the manufacturer’s instructions. Sequencing of DNA
ual (type I SMA) is currently under investigation. We didpuriﬁed by use of Wizard Minipreps (Promega) was per-
not detect abnormal patterns by SSCP or heteroduplexformed with the dsDNA Cycle Sequencing System
analysis of genomic DNA in 3/6 individuals.(Gibco BRL). Sequencing reaction products were ana-
We now describe one of the six patients with a singlelyzed by use of a 5% denaturing polyacrylamide gel.
copy of SMNT by gene-dosage analysis (patient 4659;The mutation was detected on both DNA strands in
table 2 and ﬁg. 1A and B). SSCP and heteroduplex anal-multiple subclones.
ysis of SMN exons PCR ampliﬁed from genomic DNA
in this type III SMA patient demonstrated an abnormalResults
band in exon 6. Sequence analysis of the patient’s exon
6 subclones revealed a guanine-to-thymine transversionWe describe a quantitative PCR-based method to
measure the copy number of SMNT and SMNC genes in at nucleotide 818, producing a substitution of isoleucine
for serine (S262I) at a conserved residue in the deducedorder to detect individuals with a heterozygous deletion
of the SMNT gene. Since homozygous deletions of SMNT protein (ﬁg. 1C). In order to determine whether the vari-
ant exon 6 sequence was contained within the telomericaccount for Ç95% of SMA cases, the detection of a
single copy of SMNT in a patient with clinical features or centromeric copy of SMN, the patient’s lymphocyte
RNA was ampliﬁed by RT-PCR using an exon 6 senseconsistent with SMAwould support a diagnosis of SMA.
Detection of a single copy of SMNT in an asymptomatic primer (541C618) and an exon 8 antisense primer
(541C1120) and then was subcloned and sequenced.individual would identify that person as an SMA carrier.
To test the reliability and reproducibility of the assay, The patient’s subclones containing SMNT were identi-
ﬁed by restriction-enzyme digestion, and sequence anal-we measured the SMNT copy number in a normal indi-
vidual and in a known SMA carrier determined by hap- ysis of these clones conﬁrmed that the mutant transcripts
were derived from SMNT. The nucleotide change waslotype analysis (DiDonato et al. 1994). The samples
were ampliﬁed in 10 separate PCR reactions, electropho- not observed in 200 normal chromosomes. These re-
sults, in combination with the dosage data demonstra-resed on different gels, and quantitated by densitometry.
The values from the densitometric scans and the calcu- ting that the patient possesses only one copy of SMNT,
strongly indicate that this type III SMA patient has twolated SMNT/CFTR and SMNC/CFTR ratios are shown
in table 1. The mean { SD SMNT/CFTR and SMNC/ different SMNT mutations: one SMNT allele has been
deleted, whereas the other contains a missense mutationCFTR ratios for the normal individual were 0.68 { .08
and 0.62 { .06, respectively, which represents two cop- (S262I) in exon 6.
SMNT/CFTR and SMNC/CFTR ratios were deter-ies of SMNT and two copies of SMNC. The SMA carrier
had mean { SD SMNT/CFTR and SMNC/CFTR ratios mined for 79 SMA carriers and 54 normal individuals,
to establish this assay as a valid method to distinguishof 0.28 { .06 and 0.29 { .06, respectively, which is
consistent with one copy of SMNT and one copy of between SMA carriers with one copy of SMNT and nor-
mal individuals with two copies; for example, ﬁgure 2SMNC. (It should be noted that, although we character-
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Table 1
Reproducibility of SMNT and SMNC Copy Number
NO. FROM DENSITOMETRIC SCANS FOR
TYPE CFTR CFTR-IS SMNT SMNC SMNT/CFTRa SMNC/CFTRa
Normal 118,967 114,311 71,537 69,543 .60 .58
107,932 113,891 76,390 73,369 .71 .68
64,006 73,251 48,313 33,911 .75 .53
60,206 74,688 32,022 34,595 .53 .57
54,790 55,420 36,279 31,484 .66 .57
49,754 48,086 38,716 35,801 .78 .72
126,412 117,640 85,921 81,091 .68 .64
96,863 98,561 66,955 64,919 .69 .67
49,246 37,091 29,185 30,693 .59 .62
26,518 46,443 19,126 17,042 .72 .64
(.67 { .08) (.62 { .06)
Carrier 47,802 53,273 14,930 14,214 .31 .30
52,047 63,934 14,330 12,972 .28 .25
73,957 74,941 13,279 13,395 .18 .18
17,460 22,132 3,553 4,064 .20 .23
63,749 81,768 18,218 16,557 .29 .26
120,059 102,099 46,225 46,732 .39 .39
29,175 38,230 8,531 8,325 .29 .29
29,373 40,148 7,720 9,890 .26 .34
58,207 62,618 18,274 20,373 .31 .35
45,177 47,462 15,158 14,638 .34 .32
(.28 { .06) (.29 { .06)
a Data in parentheses are mean { SD values.
shows the expected results of the SMNT and SMNC a mean { SD SMNT/CFTR ratio of 0.27 { 0.07 (one
carrier individual had two copies of SMNT; table 3).copy-number assay for normal, carrier, and affected in-
dividuals from several families. Two different popula- Twenty-two French Canadian SMA carriers (from HSJ)
had a mean { SD SMNT/CFTR ratio of 0.19 { .03 (onetions of SMA carriers previously characterized by
multicopy markers in the SMA region were analyzed in was homozygously deleted for SMNT). Interestingly,
analysis of SMNC copy number in SMA carriers revealedthis study. Fifty-ﬁve SMA carriers analyzed at OSU had
Table 2
Detection of SMA Patients with One Copy of SMNT by Dosage Analysis
No. of No. of
Patienta SMA Type SMNT/CFTR SMNC/CFTR Telomeric Copies Centromeric Copies Mutation
Control Normal .58 .55 2 2 . . .
OSU 367 I .24 .53 1 2 11-bp duplicationb
OSU 4659 III .23 .25 1 1 S262Ic
OSU 284 II/III .13 .10 1 1 Not detected
OSU 379 III .33 1.01 1 3 Not detected
HSCd I .19 .18 1 1 Not detected
FC 72e I .25 .50 1 2 Abnormal SSCP patternf
a Of the 64 patients screened at OSU, the 4 listed here had a heterozygous deletion of the SMNT gene.
b Reported by Parsons et al. (1996).
c Novel exon 6 missense mutation dercribed in the Results section.
d One of the four HSC samples had a single copy of the SMNT gene.
e One of the eight HSJ nondeletion patients had one copy of the SMNT gene, by dosage analysis.
f L. R. Simard and C. Rochette (unpublished data).
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utilizing SMNC as a standard to determine dosage of
SMNT.
Finally, SMNT and SMNC copy number was deter-
mined for individuals from several interesting SMA fam-
ilies (Burghes et al. 1994a; DiDonato et al. 1997b ). In
one case, an asymptomatic type II/III SMA carrier with
a homozygous deletion of SMNT was shown to have
four copies of SMNC, by the quantitative PCR assay
(II.1; ﬁg. 3). However, we observed another asymptom-
atic carrier deleted for SMNT who had two SMNC genes
(table 3).We also investigated three cases of haploidenti-
cal siblings from SMA families with discordant pheno-
types. We found no difference in SMNT or SMNC copy
numbers (I.4 and I.5; ﬁg. 3).
Discussion
Accurate dosage analysis is necessary in order to iden-
tify SMA carriers and to distinguish SMA compound
heterozygotes from non-5q SMA-like cases. Both of
these diagnostic applications require a method that can
differentiate between individuals with one and two cop-
ies of the SMNT gene. We applied a quantitative PCR
assay that uses an exon of the CFTR gene as a standard
Figure 1 Dosage and sequence analysis of a compound-heterozy- to determine the copy number of the SMNT and SMNC
gote 5q SMA patient. A, Autoradiograph of competitive PCR products genes. The assay also incorporates the use of two inter-
digested with DraI and run on a 6% denaturing polyacrylamide gel. nal standards (CFTR-IS and SMN-IS) to monitor the
Equal amounts of genomic DNA were added to each reaction, and the
efﬁciency of the PCR reaction and to ensure that equalSMNT and SMNC bands from patient 4659 were half the intensity that
amounts of target genomic DNA are added to each tube.was seen in the normal control. The SMNT/CFTR ratios of the normal
individual and patient 4659 were 0.51 and 0.25, respectively, demon- Similar quantitative PCR approaches have been used
strating that the patient has half the normal dosage, or one copy of successfully to identify deletions in the insulin-receptor
SMNT. B, Densitometric scan of the gel shown in A. The order of gene (Celi 1994), to detect duplications in Down syn-
peaks, from left to right, is CFTR, CFTR-IS, SMNT, SMNC, and SMN-
drome patients (Celi 1994), and to quantitate oncogeneIS. An asterisk (*) denotes the SMNT peak in the normal control (top
ampliﬁcation (Sestini et al. 1994, 1995).panel) and the patient (bottom panel). The area of the patient’s SMNT
and SMNC peaks is half that of the normal control’s. C, Comparison Since this assay uses CFTR as a standard to determine
of nucleotide and deduced amino acid sequences in the normal control’s SMNT and SMNC copy number, the problems of using
and the patient’s SMNT subclones. Patient 4659 has a GrT transversion the variable SMNC gene as a standard are avoided. Previ-
that produces a substitution of serine by isoleucine at codon 262. The
ous attempts to estimate the copy number of SMNT andbase change is denoted by an asterisk (*).
SMNC have been based on measurement of the SMNT/
SMNC ratio (Matthijs et al. 1996; Velasco et al. 1996;
Schwartz et al. 1997). The copy number of SMNC was
that 27/79 (Ç35%) had three or four copies of SMNC, determined in parents of SMA patients in cases in which
indicating that a large number of chromosomes in this it was assumed that only one copy of SMNT was present
population have two copies of SMNC on one chromo- (Velasco et al. 1996); thus this assay is limited to quanti-
some. tation of SMNC in obligate carriers. In another study, a
Fifty normal, unselected individuals had a mean { SD nonradioactive SSCP assay was used to determine SMNT
SMNT/CFTR ratio of 0.66 { .07 (table 3). One normal copy number by means of the SMNT/SMNC ratio (Mat-
individual had one copy of SMNT, which is consistent thijs et al. 1996). An elegant solid minisequencing
with the 1/40–1/60 carrier frequency for SMA in the method was used to determine the SMNT/SMNC ratio
population. We also found three normal individuals on normal and SMA chromosomes (Schwartz et al.
with three copies of SMNT. SMNC-dosage analysis in 1997). However, these methods are not suitable for car-
normal individuals revealed that only 1 (1/53, or Ç2%) rier analysis or detection of compound heterozygotes,
had three copies, 23 had two SMNC genes, 25 had one because they rely on the ratio of SMNT/SMNC without
SMNC gene, and 4 had no copies of SMNC. The results the use of an external standard. This ratio is effected by
the variation in SMNC copy number that occurs in theof this analysis clearly demonstrate the limitations of
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Figure 2 SMNT-dosage analysis of SMA carriers and their families. All members of these pedigrees were characterized previously by
linkage analysis. Families were diagnosed as follows: ‘‘I’’ (type I SMA), ‘‘II’’ (type II/III SMA), ‘‘III’’ (type II SMA), and ‘‘IV’’ (type II SMA).
The normal control is represented as ‘‘N.’’ SMA carriers are represented as half-blackened boxes, whereas affected SMA patients are represented
as completely blackened boxes. The SMNT/CFTR ratios for SMA carriers are half the ratio for the normal control, whereas affected SMA
patients are deleted for SMNT.
normal population, and it does not account for the pos- hydroxyl group. The phenotype of this chronic type III
SMA patient correlates well with the possibility that hesibility of more than one SMNT gene on a chromosome.
Utilizing the competitive PCR assay, we quantitated has a combination of a severe (deleted) and a milder
(S262I missense mutation) SMNT allele. This serine resi-the SMNT copy number in patients with clinical features
consistent with SMA without homozygous deletions of due is conserved in both mouse (DiDonato et al. 1997a ;
Viollet et al. 1997) and Caenorhabditis elegans (cosmidSMNT. We found that a majority (Ç92%) had normal
SMNT dosage. Although SMA patients with two identi- C41G7; GenBank accession Z81048) SMNT proteins.
This mutation was identiﬁed simultaneously by Hahnencal, nondeleted SMNT alleles were identiﬁed in cosangui-
nous Spanish families (Bussaglia et al. 1995), the esti- et al. (1997). Talbot et al. (1997) report a clustering
of missense mutations in a C-terminal dodecapeptidemated frequency of this event is rare in a random
population. Although further clinical evaluation may region, highly conserved in Saccharomyces pombe and
C. elegans homologues, which may be an importanthave excluded some of these patients from SMNT-dos-
age testing, the results of our analysis clearly indicate binding domain. The S262I missense mutation identiﬁed
in a type III SMA patient lies just upstream of this region,that the clinical features of SMA are shared by other
neuromuscular disorders. In addition, we did not detect indicating that the conformation of the region upstream
of the dodecapeptide is also important for SMN func-abnormal patterns by SSCP or heteroduplex analysis in
3/6 patients identiﬁed with a single copy of SMNT. Possi- tion.
Since SMA is one of the most common lethal geneticble explanations include the following: the mutation
may be outside of the screened region, there may be a disorders, with a carrier frequency of 1/40–1/60, devel-
opment of a rapid, direct carrier test would be beneﬁcialduplication or a deletion of a region other than exon 7,
or individuals with one copy of SMNT may be SMA to many families. SMA carrier testing presently is being
done by linkage analysis and is subject to the potentialcarriers. We would expect Ç2% (1.5/76) of this popula-
tion to be SMA carriers, and therefore 1 or 2 of these problems of recombination events, de novo mutations,
and the difﬁculty of obtaining DNA samples from vari-patients could be an SMA carrier with another neuro-
muscular disorder. ous family members. The advantage of our assay is that
it directly measures SMNT copy number and circum-Our assay rapidly identiﬁed potential SMA 5q com-
pound heterozygotes and deﬁned a limited population vents these problems. The SMNT gene-dosage assay
identiﬁed a single copy of SMNT in most SMA carriers,of patients for SMNT mutation analysis. We identiﬁed
a novel exon 6 missense mutation in a type III SMA except for one that was homozygously deleted and one
that had two copies of SMNT. Possible explanations forpatient with one copy of SMNT. The serine-to-isoleucine
substitution at codon 262 in exon 6 introduces an amino this ﬁnding include a de novo mutation (Melki et al.
1994, Wirth et al. 1995b), somatic mosaicism, or oneacid with a bulkier side chain and the net loss of a
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Table 3
SMNT and SMNC Copy Number in Normal Individuals and SMA Carriers
No. of Genotype
Type Individuals (SMNT, SMNC) SMNT/CFTRa SMNC/CFTRb
Normal 3 3, 1 .92 { .12c .22 { .06
1 2, 3 .62 .91
23 2, 2 .67 { .08 .64 { .07
22 2, 1 .67 { .06 .27 { .04
4 2, 0 .60 { .10 0
1 1, 3 .30 1.10
SMA carriers:
OSU:
SMA I 1 2, 1 .76 .38
4 1, 3 .28 { .09 1.06 { .13
6 1, 2 .33 { .06 .68 { .09
5 1, 1 .27 { .08 .32 { .09
SMA II 8 1, 3 .26 { .05 .99 { .10
7 1, 2 .23 { .07 .62 { .11
2 1, 1 .29 { .05 .26 { .01
SMA II/III 2 1, 3 .29 { .18 1.09 { .04
4 1, 2 .25 { .10 .63 { .14
1 1, 1 .27 .27
SMA III 3 1, 4 .25 { .06 1.40 { .09
6 1, 3 .28 { .03 1.02 { .15
5 1, 2 .31 { .05 .70 { .12
2 1, 1 .28 { .04 .29 { .02
HSJ:
SMA I 2 1, 2 .21 { .02 .41 { .08
2 1, 1 .18 { 0 .17 { .02
1 0, 2 0 .41
SMA II 1 1, 3 .21 .57
3 1, 2 .20 { .01 .37 { .03
SMA III 3 1, 3 .22 { .02 .62 { .07
9 1, 2 .19 { .04 .41 { .09
2 1, 1 .17 { .01 .18 { 0
a The average for 50 normal individuals with two copies of SMNT was .66 { .07; for the OSU sample,
the average for 55 carriers with one copy of SMNT was .27 { .07, whereas, for the HSJ sample, for 22
carriers with one copy of SMNT it was .19 { .03.
b SMNC copy number was calculated for OSU samples by dividing the SMNC/CFTR ratio by .34 (average
SMNT/CFTR of .27 / 1 SD, as the maximum ampliﬁcation of one copy of SMN). It should be noted that
this method may underestimate SMNC copy number in some cases, since the SMNC/SMNT ratio is not
equivalent.
c The quantitative PCR assay was repeated in four separate reactions to conﬁrm these results.
chromosome with two SMNT genes. Since this carrier 1995b). This would indicate that the copy number of
SMN also varies on chromosomes. Quantitation ofindividual has two affected children with the same hap-
lotype, a de novo mutation is unlikely. Although we SMNT copy number in normal individuals revealed that
3/53 had three copies of SMNT, indicating that twocannot distinguish between the latter two possibilities,
the case of two SMNT genes on one chromosome is copies are present on one chromosome. Velasco et al.
(1996) previously reported a carrier mother and fetuslikely, on the basis of our ﬁnding of 3/106 normal chro-
mosomes with two SMNT genes. with two SMNT genes on one chromosome. Multiple
copies of SMN genes on one chromosome may haveAnalysis of SMNT copy number in 54 normal individ-
uals revealed several interesting points. First, one carrier arisen by either unequal crossing-over or a sequence-
conversion event (Hahnen et al. 1996).individual with a single SMNT gene was identiﬁed,
which is consistent with the estimated carrier frequency The ﬁnding of two SMNT genes on a single chromo-
some has serious counseling implications, because a car-of 1/40–1/60. Second, the marker Ag1-CA lies at the
5 end of the SMN gene, and this marker varies on rier individual with two SMNT genes on one chromo-
some would be misdiagnosed by SMNT copy-numberchromosomes (DiDonato et al. 1994; Wirth et al.
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pected genotype ratios (x2 Å 1.6). It should be noted
that this assay does not distinguish between the geno-
typic groups (1,1) or a single copy of SMNC on each
chromosome from (2,0) or two copies of SMNC on a
single chromosome. Because no normal individuals with
four copies of SMNC were observed, the precise estima-
tion of the frequency of the (2,0) genotype by use of the
maximum-likelihood method is not possible. However,
the frequency of the (2,0) genotype would be predicted
to be negligible. A larger number of individuals will
have to be typed to allow accurate assessment of these
genotype frequencies.
An interesting ﬁnding from these studies is that 27/
79 (4/21 type I and 23/58 types II and III) SMA carriers
Figure 3 SMNT- and SMNC-dosage analysis of two atypical had three or four copies of SMNC, indicating that there
SMA families. Family I (type II SMA) has been described previously, were two copies of SMNC on one or both chromosomes,
by Burghes et al. (1994a), as SMA6. Although linkage analysis demon-
whereas only 1/53 (Ç2%) of the normal individuals hadstrated that individuals I.4 and I.5 are haploidentical, they have re-
three copies of SMNC. Previous studies, using themarkably different phenotypes. Individual I.4 had onset at 1 year of
age and never walked, whereas individual I.5 was still able to walk marker Ag1-CA, demonstrated a correlation between
at 20 years of age. Individuals I.4 and I.5 have a homozygous deletion the number of copies of Ag1-CA and SMA phenotype
of SMNT and have SMNC/CFTR ratios of 0.95 and 0.88, respectively. (DiDonato et al. 1994; Wirth et al. 1995b). Since Ag1-
Since both siblings have three copies of SMNC, the different pheno-
CA lies at the 5 end of the SMN genes, this implies thattypes cannot be explained by a difference in SMNC copy number.
type I patients have deleted chromosomes and that typeFamily II (type II/III SMA) represents a case of an asymptomatic carrier
parent (II.1) homozygously deleted for SMNT. The SMNC/CFTR ratio II/III patients have one deleted chromosome and a gene
is consistent with four copies of the SMNC gene. In table 2, individual conversion on the other chromosome. The study by Ve-
II.3 is designated as ‘‘OSU 284’’; and he currently is being investigated lasco et al. (1996), which demonstrated that three copies
to detect a mutation in the single copy of SMNT present. Normal and
of SMNC predominated in type II/III families is consis-carrier controls are represented as ‘‘N’’ and ‘‘C,’’ respectively. Carrier
tent with this interpretation. Therefore, the increase inindividuals are represented by half-blackened boxes, whereas affected
individuals are represented by completely blackened boxes. SMNC copy number reported here provides evidence to
support previous work indicating that a large number
of type II/III SMA chromosomes contain gene conver-
sions as opposed to deletions (DiDonato et al. 1994,analysis. If both a prior probability of 1/40–1/60 of
being an SMA carrier in the general population and a 1997; Wirth et al. 1995b; Hahnen et al. 1996; van der
Steege et al. 1996). We currently are preforming a moreconditional probability of Ç2% of carrying two SMNT
genes on one chromosome (4/185 chromosomes; i.e., detailed analysis of gene conversion, using this dosage
assay to determine the proportion of gene conversions3/106 normal chromosomes and 1/79 ‘‘normal’’ chro-
mosomes from SMA carriers) are assumed, then a nor- in different SMA types.
Determination of SMNC gene-copy number in SMAmal SMNT/CFTR ratio on the basis of gene-dosage anal-
ysis would reduce the risk of being an SMA carrier to family members led to some interesting observations.
Individual II.3 (ﬁg. 3) previously had been identiﬁed as1/2,000–1/3,000. Thus, although the ﬁnding of normal
dosage signiﬁcantly reduces the risk of being a carrier, an affected patient who was not homozygously deleted
for SMNT, on the basis of SSCP and restriction-enzymeour results show that there is still a small recurrence risk
of future affected offspring for individuals with normal analysis (DiDonato et al. 1997b ). These same tests dem-
onstrated that individual II-1, the asymptomatic carrierdosage.
Last, quantitation of SMNC gene-copy number in nor- mother of II-3, was completely deleted for SMNT. Sev-
eral reports describe the existence of unaffected individ-mal individuals revealed that 1/53 had three copies,
23/53 had two copies, 25/53 had one copy, and 4/53 uals with a homozygous deletion of SMNT (Cobben et
al. 1995; Hahnen et al. 1995; Wang et al. 1996). Thiswere homozygously deleted for SMNC. The observed
genotypes for SMNC in our normal population were asymptomatic carrier has four copies of SMNC, which
could suggest that the number of copies of SMNC in this1.9% (three copies), 43.4% (two copies), 47.2% (one
copy), and 7.5% (no copies). The expected genotypes, individual compensates for the lack of SMNT. However,
this situation does not apply to all asymptomatic indi-on the basis of Hardy-Weinburg for a three-allele sys-
tem, are 2.5% (three copies), 46.9% (two copies), viduals, since we observed (1) only two SMNC genes in
a second asymptomatic carrier (table 3) and (2) SMA41.3% (one copy), and 9.3% (no copies). The observed
genotype ratios do not differ signiﬁcantly from the ex- individuals with four copies of SMNC. In addition, our
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N, Nadkarni N, DiDonato CJ, et al (1994a) Linkage map-group (Burghes et al. 1994a) and others (Mu¨ller et al.
ping of the spinal muscular atrophy gene. Hum Genet 93:1992; Rudnik-Scho¨neborn et al. 1994) have described
305–312SMA families in which two sibs have remarkably discor-
Burghes AHM, Ingraham SE, McLean M, Thompson TG, Mc-dant phenotypes. In the cases analyzed in this study
Pherson JD, Kote-Jarai Z, Carpten JD, et al (1994b) A(SMA6 and SMA14 [Burghes et al. 1994a] and SMA75
multicopy dinucleotide marker that maps close to the spinal
[DiDonato et al. 1997b ]), no difference in SMNC copy muscular atrophy gene. Genomics 21:394–402
number was detected between the affected and unaf- Burglen L, Lefebvre S, Clermont O, Burlet P, Viollet L, Cruaud
fected/mildly affected individuals (I.4 and I.5; ﬁg. 3), C, Munnich A, et al (1996) Structure and organization of
indicating that a change in SMNC copy number is not the human survival motor neurone (SMN) gene. Genomics
the mechanism responsible for discordant phenotypes in 32:479–482
Bussaglia E, Clermont O, Tizzano E, Lefebvre S, Burglen L,these families. Studies at the RNA and protein levels
Cruaud C, Urtizberea JA, et al (1995) A frame-shift deletionshould elucidate whether the critical component in the
in the survival motor neuron gene in Spanish spinal muscu-unaffected/mildly affected individuals is the amount of
lar atrophy patients. Nat Genet 11:335–337full-length SMN produced.
Carpten JD, DiDonato CJ, Ingraham SE, Wagner-McPhersonIn conclusion, we report a powerful, rapid quantita-
C, Nieuwenhuijsen BW, Wasmuth JJ, Burghes AHM (1994)tive PCR assay and demonstrate its clinical application
A YAC contig of the region containing the spinal muscular
for detection of compound-heterozygote 5q SMA pa- atrophy gene (SMA): identiﬁcation of an unstable region.
tients and SMA carriers. The quantitative SMNT and Genomics 24:351–356
SMNC copy-number assay increases the sensitivity of Celi FS, Cohen MM, Antonarakis SE, Wertheimer E, Roth J,
diagnosis of SMA and allows for direct carrier testing. Shuldiner AR (1994) Determination of gene dosage by a
This assay now can be used to quantitate SMNC and quantitative adaptation of the polymerase chain reaction
(gd-PCR): rapid detection of deletions and duplications ofSMNT genes in SMA families, to provide insight into the
gene sequences. Genomics 21:304–310frequency and mechanisms of gene-conversion events.
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